Akorn, Inc., together with its subsidiaries, engages in the manufacture and marketing of diagnostic and therapeutic pharmaceuticals in the areas of ophthalmology, rheumatology, anesthesia, and antidotes primarily in the United States. It operates in three segments: Ophthalmic, Hospital Drugs and Injectables, and Contract Services. The Ophthalmic segment manufactures and markets diagnostic and therapeutic ophthalmic pharmaceutical products. Its diagnostic products include mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, and angiography dyes, which are primarily used in the office setting. The segment’s therapeutic products include antibiotics, anti-infectives, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications. Its nonpharmaceutical products comprise various artificial tear solutions, preservative-free lubricating ointments, eyelid cleansers, vitamin supplements, and contact lens accessories. The Hospital Drugs and Injectable segment manufactures and markets various injectable pharmaceutical products, including antidotes, anesthesia, and products used in the treatment of rheumatoid arthritis and pain management. Its products are marketed to hospitals through wholesalers and other national account customers, as well as directly to medical specialists. The Contract Services segment manufactures products for third party pharmaceutical and biotechnology customers. The company serves physicians, optometrists, hospitals, wholesalers, group purchasing organizations, and other pharmaceutical companies. Akorn, Inc. has strategic partnerships with Strides Arcolab Limited; Akorn-Strides, LLC; FDC Limited; Hameln Pharmaceuticals Gmbh; and Cipla, Ltd. It also has a licensing, development, and supply agreement with Sofgen Pharmaceuticals to develop an ANDA oral drug product for women's healthcare. The company was founded in 1971 and is headquartered in Buffalo Grove, Illinois.